By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has signed an agreement with BioMarin Pharmaceutical to perform BRCA1 and BRCA 2 mutation testing for the drug firm's PARP inhibitor drug candidate, Myriad said after the close of the market on Wednesday.

The testing will be done on patients enrolled in BioMarin's Phase I and Phase II clinical study of its PARP inhibitor called BMN 673 for patients with advanced or recurrent tumors.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.